Establishment of anti-mesothelioma monoclonal antibodies by unknown
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Abstract 
Background: Mesotheliomas are aggressive, therapy-resistant tumors that are predicted to increase in incidence at 
least until 2020. The prognosis of patients with mesothelioma is generally poor because they are typically diagnosed 
at a late stage and their tumors are resistant to current conventional therapies. For these reasons, improved diagnosis 
and therapy are urgently required. To address these issues, the aim of our research was to develop novel mesotheli-
oma-specific monoclonal antibodies (mAbs) as diagnostic and therapeutic agents.
Methods: To develop anti-mesothelioma mAbs useful for diagnosis and therapy, we repeatedly immunized a BALB/c 
mouse with viable mesothelioma cells, alternating between those from three mesothelioma cell lines. We hybridized 
the spleen cells from this immunized mouse with P3U1 myeloma cells. We then screened supernatants harvested 
from the hybridoma clones by assessing whether they bound to a mesothelioma cell line not used for immuniza-
tion and altered its morphology. We designed this developmental strategy to reduce the risk of obtaining clonotypic 
mAbs against a single mesothelioma cell line.
Results: Our newly generated mouse anti-human mAbs immunostained clinical samples of mesotheliomas. One of 
the newly generated mAbs did not react with any other tumor cell line tested. Two other mAbs significantly inhibited 
the proliferation of mesothelioma cells.
Conclusion: These newly generated anti-mesothelioma mAbs are potentially useful as diagnostic and therapeutic 
agents for mesothelioma. Moreover, our novel strategy for establishing antitumor mAbs may facilitate the develop-
ment of new diagnostic and therapeutic techniques for mesotheliomas and other malignancies.
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Background
Mesothelioma is an aggressive tumor that develops from 
mesothelial cells, which line the pleural, peritoneal, and 
pericardial cavities. The development of mesothelioma 
is usually associated with chronic exposure to asbestos 
fibers [1, 2]. The worldwide incidence of mesothelioma 
is increasing and is expected to peak in approximately 
2020 because of the long latent period between expo-
sure to asbestos fibers and the appearance of disease [3]. 
Asbestos continues to be mined in Russia, China, Bra-
zil, Kazakhstan and other countries [4]. Asbestos is still 
imported and used in brake pads, gaskets, etc., even in 
the US [4]. Diagnosis based on chest X-ray and computed 
tomography (CT) findings must be confirmed by cyto-
logic serous effusion examination or biopsy [5–7].
Immunohistochemistry has significantly enhanced 
the accuracy of cytology, although reaching a diagnosis 
remains frequently difficult [8–10]. Although many diag-
nostic procedures are available, no single test unambigu-
ously distinguishes mesothelioma from other carcinomas 
or even benign from malignant cells. The correct com-
bination of antibodies used to detect positive or nega-
tive markers should be employed and a comprehensive 




*Correspondence:  matsuoka@juntendo.ac.jp 
2 Departments of Pathology and Oncology, Juntendo University School 
of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
Full list of author information is available at the end of the article
Page 2 of 13Mizutani et al. BMC Res Notes  (2016) 9:324 
Mesothelioma is categorized histologically as epithe-
lioid, sarcomatoid, biphasic, and desmoplastic, among 
others [9]. The histological subtypes help predict prog-
nosis and the choice of treatment. Therefore, it is impor-
tant to analyze pathological tissue using an appropriate 
combination of antibodies for diagnosis and classifica-
tion. Nevertheless, many cases are difficult to diagnosis 
[12–16].
Although an anti-CD26 mAb is a promising candidate, 
no effective molecular target for therapy exists [17, 18]. 
Therefore, the development of novel anti-mesothelioma 
mAbs may facilitate diagnosis and serve as therapeu-
tic agents. Subsequent to the development of mAbs by 
Köhler, Milstein, and Jerne in 1975 [19], excessively large 
number of mAbs were generated as diagnostic [20, 21] or 
therapeutic reagents [22].
Diagnostic or therapeutic mAbs are now typically gen-
erated by immunizing mice with synthetic peptides or 
target antigens that are purified to some extent [23, 24]. 
Except for nude or SCID mice, mice reject inoculated live 
malignant human tumor cells. During the first or sec-
ond challenge, tumor cells may be primarily killed by NK 
and CD8 cytotoxic T cells or ingested by macrophages. 
However, during the course of repeated immunizations, 
mouse B cells are generated that produce antibodies 
against the tumor cells. These antibodies probably make 
a major contribution to the rejection of the tumor cells. 
This hypothesis served as the rationale for our experi-
ments that were aimed at establishing anti-mesothelioma 
mAbs. We report here the generation of anti-human 
mesothelioma mAbs for diagnosis and treatment. This 
was accomplished by immunizing a mouse with live mes-
othelioma cell lines. The hybridomas were selected for 
their ability to produce antibodies that bound to meso-
thelioma cell lines not used for immunization. Some of 
these newly established mAbs reacted specifically with 
mesothelioma cells or inhibited their proliferation.
Methods
Mice
Female BALB/c mice (6–8 weeks of age) were purchased 
from Charles River Japan (Yokohama, Japan) and housed 
in a specific pathogen-free facility in micro-isolator 
cages. Animal experiments were conducted following 
protocols approved by the Animal Care Committee of 
Juntendo University of Medicine.
Cells
The human mesothelioma cell lines ACC-MESO-1 and 
ACC-MESO-4 were purchased from the RIKEN Cell 
Bank (Ibaraki, Japan), JMN was a kind gift from Dr. 
Brenda Gerwin and others (NCI-H226, MSTO-211H, 
NCI-H28 and NCI-H2452) were purchased from the 
American Type Culture Collection (ATCC) (Manassas, 
VA). The lung cancer cell lines (A549, PC9, Lu24, and 
WA-hT), and the HuH-7 (hepatocellular carcinoma), 
MKN1 (gastric cancer), OVK18 (ovarian cancer), VMRC-
RCW (renal cell carcinoma) cell lines were purchased 
from the RIKEN Cell Bank. The MCF7 (breast cancer), 
KP3 (pancreatic cancer), and HCT 116 (colon cancer) cell 
lines were purchased from ATCC. All cells were cultured 
and maintained in RPMI-1640 medium (GIBCO, Grand 
Island, NY) supplemented with 10  % heat-inactivated 
fetal calf serum.
Antibodies
The mouse anti-HLA class I (HLA class-A, B, C) mAb 
(clone: W6/32) was purchased from Harlan Laboratories 
Inc. (IN). Alexa Flour® 488-conjugated goat anti-mouse 
IgG was purchased from Invitrogen (CA). Mouse IgG 
was purchased from Abcam (Cambridge UK). The mAbs 
for WT-1 (clone: 6F-H2), Calretinin (clone: DAK-Calret 
1), Podoplanin (clone: D2-40), Cytokeratin 5/6 (clone: 
D5/16 B4), EMA (clone: E29), Carcinoembryonic Anti-
gen (CEA) (clone: II-7), TTF-1 (clone: 8G7G3/1), and 
Epithelial-Related Antigen (clone: Moc-31) were pur-
chased from DAKO. The mAb against Mesothelin (clone: 
22A31) and anti-GLUT-1 polyclonal Ab were purchased 
from IBL (Japan). Anti-CD26 mAbs (clone 1F7, 5F8) 
were established in our laboratory [25].
Anti-CD25 mAb (clone: BC96) and mouse Ig G1 iso-
type control (MOPC-21) were purchased from TONBO 
biosciences (CA).
Generation of mAbs against mesothelioma cells
An eight-week-old female BALB/c mouse was immu-
nized alternately using intraperitoneal injections of 
2–5  ×  106 living cells derived from the mesothelioma 
cell lines ACC-MESO4, MSTO-211H, and NCI-H226 
every 2  weeks for 3  months. Three days after the last 
immunization, spleen cells were fused with P3U1-non-
producing myeloma cells using polyethylene glycol 4000 
(Merck, Darmstadt, Germany) and cultured in RPMI-
1640 supplemented with 10  % fetal calf serum (FCS, 
Japan Bioserum, Fukuyama, Japan), 5 % BriClone (NICB, 
Dublin, Ireland), and HAT (Invitrogen, Tokyo, Japan) 
in the wells of 96-well flat-bottom plates (Costar, Corn-
ing Incorporated, Corning, NY). Hybridoma superna-
tants were screened for reactivity with the mesothelioma 
NCI-H2452 cells, which were not used for immuniza-
tion. Light microscopy revealed morphological changes 
and an aggregation of target cells induced by incubation 
with supernatants of hybridoma clones after 72  h. The 
reactivity of hybridoma supernatants for the other mes-
othelioma cell lines was also determined. Four hybrido-
mas, JMAM1–4, were selected and cloned using limiting 
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dilution. The isotype of these mAbs was IgG1, and they 
cross-reacted widely with mesothelioma cell lines.
Flow cytometric (FACS) analysis
The expression of the molecular target(s) of the newly 
established mouse anti-human mesothelioma mAbs was 
determined using a BD LSRForessa™ cell analyzer (BD 
Bioscience, CA, USA). Briefly, the human mesothelioma 
cell lines and the cell lines derived from other tumors 
were incubated with the supernatants of hybridomas and 
then with Alexa Flour® 488-conjugated rat anti-mouse 
IgG (BD Bioscience) on ice.
Inhibition test
NCI-H226 cells were first incubated with already known 
existing Abs and further incubated with Alexa Flour® 
488-labeled JMAM mAbs.
Immunocytochemistry
Samples of pleural effusions submitted to the Depart-
ment of Pathology, Juntendo University, were used for 
immunohistochemistry and other histological staining 
procedures. Three representative cases of cytologically 
diagnosed mesothelioma were used for immunohisto-
chemistry, and all cases were stained with positive and 
negative antibody panels of diagnostic antibodies to con-
firm the diagnosis of mesothelioma. Cell smears were 
fixed in 95 % ethanol for Papanicolaou and immunostain-
ing, or air-dried for May-Grunwald-Giemsa staining. Cell 
sediments were fixed with ethanol and embedded in par-
affin for immunostaining. Sections were deparaffinized 
using three changes of xylene and rehydrated with a 
graded series of ethanol concentrations. Endogenous per-
oxidase was inactivated with 0.3  % H2O2 in phosphate-
buffered saline for 10 min. Samples were incubated with 
the novel anti-mesothelioma mAbs JMAM1−4 at 4  °C 
overnight in a humidified chamber, followed by the addi-
tion of EnVision™ + DualLink (DAKO) and 3.3′-diamin-
obenzidine (Dojindo Laboratories) as the chromogen. 
Cell smears and cell-block sections were counterstained 
to reveal nuclei using Mayer’s hematoxylin. For all cases, 
we stained cell block sections using antibodies against 
EMA, Podoplanin, GLUT-1, Calretinin, WT-1, Cytokera-
tin 5/6, Mesothelin, CEA, TTF-1, and epithelial-related 
antigen to confirm the diagnosis of mesothelioma 
(Table 1).
In vitro proliferative assay of mesothelial cells incubated 
with mAbs
MSTO-211H cells (1  ×  104 cells/well) were incubated 
with 10  % FCS-RPMI supplemented with 0.005–0.4  µg/
ml of JMAM1–4 mAbs for 48 h at 37 °C in an atmosphere 
containing 5 % CO2. The culture was pulsed with 0.5 μCi 
of tritiated thymidine, [3H]-TdR, for the final 24  h. The 
incorporation of [3H]-TdR was determined using scintil-
lation counting. Data are expressed as the mean ± stand-
ard deviation (SD) of triplicate samples and represent 
three separate experiments.
Wound‑healing assay
Mesothelioma NCI-H226 cells were seeded in 6-well 
plates (Corning) and grown to 90 % confluence in RPMI 
plus 10  % FCS. The cell monolayer was wounded with 
the tip of an Eppendorf P200 pipette. After wounding, 
the wells were washed with media to remove dead cells 
and debris. The wells were treated with either 3 µg/ml of 
anti-mesothelioma mAbs (JMAM1–4) or a control IgG 
(3  µg/ml) and cultured further. The wound closure was 
observed after 24 h.
Cell invasion assay
For the cell invasion test, a Corning Matrigel Invasion 
Chamber (8-μm pore size, coated with Matrigel; Discov-
ery Labware Inc., Bedford, MA, USA) was placed into 
the wells of 24-well culture plates; RPMI-1640 medium 
with 10  % serum and JMAM1–4 mAbs (each 10  μM) 
were added into the lower chamber; then, 2 × 104 NCI-
H226 cells in serum-free RPMI-1640 medium was added 
to the upper chamber and cultured at 37  °C. After 15 h 
of incubation, the cells on the upper surface of the filter 
membrane that had not migrated were gently scraped 
away with a cotton swab. The invading cells on the lower 
surface of the filter membrane were fixed with metha-
nol, stained with Diff-Quick™ (Sysmex), and counted as 
described above. All tests were performed in triplicate.
Statistical analysis
The data were analyzed using Student’s t test. The results 
are expressed as the mean ±  SD and P values of <0.05 
were considered significant. Statistical analyses were per-
formed using SPSS 14.0 software (IBM, NY).
Results
Morphological changes of mesothelioma cell lines induced 
by the newly generated mAbs
We found that the newly generated four mAbs repro-
ducibly induced morphological changes in a mesothe-
lioma cell line that was not used for immunization. Light 
microscopy revealed that the morphology of the NCI-
H2452 cells changed from spindle-shaped to round, and 
the numbers of these cells decreased after incubation 
with JMAM1–4 mAbs for 72  h compared with control 
mouse IgG (Fig.  1a, upper column). These morphologi-
cal changes indicated that the mAbs bound the meso-
thelial cell lines. These findings were also reproduced 
using MSTO-211H cells that were used for immunization 
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(Fig. 1a, lower column). Furthermore, these mAbs aggre-
gated MSTO-211H cells. Taken together, these findings 
indicate that the newly established mAbs reacted with 
the mesothelial cell lines.
Analysis of the binding of mAbs to the mesothelial cell 
lines
The reactivity of the mAbs against the mesothelial cell 
lines was determined using FACS analysis. JMAM1, 
JMAM2 and JMAM3 mAbs stained the epithelial (ACC-
MESO-4, JMN) and sarcomatous (MSTO-211H, H2452, 
H28 and MESO-1) cell lines. In contrast, JMAM4 stained 
the epithelial cell lines but not the sarcomatous cell lines 
(Fig. 1b).
Competitive inhibition of JMAM mAbs with established 
mAbs
To determine whether the newly established JMAM 
mAbs bind to the same epitope of the already existing 
Abs, we performed an inhibition test by flow cytometry.
NCI-H226 cells were incubated with JMAM mAbs fol-
lowed by staining with existing Abs already known to 
bind to mesothelioma [anti-calretinin, anti-podoplanin 
(D2-40), anti-GLUT-1, anti-CD25 (BC96), anti-CD26 
(1F7, 5F8), anti-C-ERC/mesothelin (22A31)]. (Fig. 2).
Anti-calretinin was able to partially inhibit the staining 
of the NCI-H226 mesothelioma cell line with JMAM2 
mAb. This result indicates that the JMAM2 determi-
nant is strongly related to calretinin; however, the other 
JMAM mAbs have no relationship with already existing 
Abs, they may bind to mesothelioma cells.
Analysis of the binding of mAbs to other tumor cell lines
Using FACS analysis, we next determined whether the 
mAbs bound to lung cancer cell lines. Binding of JMAM1 
to epithelial-type lung cancer cell lines (A549 and PC9) 
was not detectable. In contrast, it bound to the small-cell 
lung cancer cell lines WA-hT and Lu24. The extent of 
binding of JMAM2 and JMAM3 mAbs to lung cancer cell 
lines varied. The JMAM4 mAb did not bind to any of the 
lung cancer cell lines (Fig. 3a).
To determine the cross-reactivity of these novel anti-
mesothelioma mAbs to cell lines derived from tumors 
other than those of the lung, we used FACS analysis 
to determine their ability to react with MCF7 (breast 
cancer), HuH-7 (liver cancer), KP3 (pancreatic can-
cer), MKN-1 (gastric cancer), HCT 116 (colon can-
cer), OVK18 (ovarian cancer), and VMRC-RCW (renal 
cell carcinoma) cell lines. The JMAM1 mAb only cross 
reacted with the VMRC-RCW cell line. JMAM4 mAbs 
did not react detectably with any of these carcinoma cell 
lines. The JMAM2 mAb slightly or significantly stained 
all carcinoma cell lines tested. The JMAM3 mAb did not 
stain the liver or pancreatic cancer cell lines; however, 
it lightly stained a gastric cancer cell line and strongly 
stained breast and colon cancer cell lines (Fig. 3b). Taken 
together, these data indicate that the JMAM1 mAb dis-
tinguished mesothelioma and small-cell lung cancer cells 
from epithelial lung cancer cells as well as any other can-
cer cells derived from these tissues except for renal cell 
carcinoma. These data also suggesting that JMAM4 mAb 
may distinguish epithelial mesotheliomas from all other 
cancers.
Table 1 Antibodies used in this study and immunocytochemical reactivity
Antibody Clone Source Dilution Specimen Case 1 Case 2 Case 3
JMAM1 Our labolatory Undiluted cell supernatant Cell smear + + +
JMAM2 Our labolatory Undiluted cell supernatant Cell smear + + +
JMAM3 Our labolatory Undiluted cell supernatant Cell smear + + +
JMAM4 Our labolatory Undiluted cell supernatant Cell smear + + +
WT-1 6F-H2 DAKO 1:200 Cell block + ± +
Carletnin Dak-Calret 1 DAKO 1:100 Cell block + + +
Mesothelin 22A31 IBL 1:1000 Cell block + + +
Podoplanin D2–40 DAKO 1:200 Cell block + + +
CK5/6 D5/16B4 DAKO 1:50 Cell block + + +
EMA E29 DAKO 1:100 Cell block + + +
GLUT-1 5B12.3 IBL 1:1000 Cell block + + +
CEA II-7 DAKO 1:50 Cell block − − −
TTF-1 8G7G3/1 DAKO 1:100 Cell block − − −
Epithelial-related antigen Moc-31 DAKO 1:100 Cell block − − −
Page 5 of 13Mizutani et al. BMC Res Notes  (2016) 9:324 




















Fig. 1 Reactivity of JMAM mAbs with mesothelioma cell lines. a Morphological changes by JMAM mAbs. NCI-H2452 cells were incubated with 
hybridoma supernatants for 72 h and observed using visible light microscopy. RPMI-1640 medium with 10 % FCS served as the control (upper 
column). These findings were also reproduced using MSTO-211H cells (lower column). b Flow cytometry analysis of JMAM mAb reactivity. Mesothe-
lioma cell lines were incubated with the hybridoma supernatant (green histogram) or control mouse IgG (black histogram), subsequently stained 
with Alexa Flour®-488 labeled anti-mouse IgG Ab and analyzed using flow cytometry
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Alexa488 labeled JMAM mAb.                    
















Fig. 2 Competitive inhibition of JMAM mAbs with established mAbs. Staining profiles of JMAM mAbs without or with already existent mAbs are 
shown by green lines or red lines, respectively
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Analysis of mesotheliomas by mAbs
To determine whether these newly generated mAbs were 
suitable for immunohistochemical staining of formalin-
fixed tissue sections, we used them to analyze surgically 
resected mesothelioma tissue specimens. Unfortunately, 
we did not detect staining of formalin-fixed paraffin-
embedded tissue specimens (data not shown). The anti-
gens recognized by the mAbs might have been masked or 
antigenically inactivated by formalin fixation.
Body fluid retention is one of the symptoms of many 
patients with malignant mesothelioma who are often 
diagnosed with mesothelioma by body fluid cytological 
examination. Therefore, we investigated whether the mAbs 
reacted with cytological samples using body fluid specimens 
that were fixed with ethanol. We analyzed specimens from 
three patients with malignant mesothelioma and those from 
patients suspected to have malignant mesothelioma (Fig. 4). 
All materials were prepared from pleural effusions.
Fig. 3 Reactivity of JMAM mAbs with other cell lines. Epithelial-type and small-cell-type lung cancer (a) and other cancer cell lines (b) were incu-
bated with hybridoma supernatants (green histogram) or control mouse IgG (black histogram), subsequently stained with Alexa Flour® 488-labeled 
anti-mouse IgG Ab and analyzed using flow cytometry
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Case 1 Many cell clusters were present, including tight 
and loose clusters with flattened cellular borders. Indi-
vidual cells showed wide variation in shape and size, 
ranging from small to very large. The JMAM1–4 mAbs 
stained membranes, whereas the JMAM2 mAb stained 
the cytoplasm and the membrane.
Case 2 The few malignant cells present were judged 
Class III by Papanicolaou classification. All mAbs stained 
membranes clearly.
Case 3 Present were small to large clusters with knobby 
borders and a single-cell population. These cells had low 
nuclear: cytoplasmic ratios, but occasionally showed 
macronucleoli. The staining of membranes by mAbs 
JMAM1–4 was distinct. Antibodies against Podoplanin, 
Mesothelin, EMA, and GLUT-1 stained cell-block speci-
mens, which confirmed these atypical cells as derived 
from mesothelioma (Table 1). Because JMAM1–4 mAbs 
stained the membranes of all mesothelioma specimens 
tested, they may be useful for the cytological testing of 
pleural effusions of patients with mesothelioma.
Histopathology and cytology of lung and mesothelial cells
Reactive normal pleura and lung immunoreactive fea-
tures are shown in Fig. 5. Reactive pleural effusion mes-
othelial cells stained with JMAM mAbs (a); however, 
normal pleural mesothelium and lung tissue did not stain 
with JMAM mAbs (b, c).
Analysis of the effects of mAbs on the proliferation 
of mesothelioma cells
We next tested whether the mAbs inhibited the prolifera-
tion of the MSTO-211H mesothelioma cell line (Fig. 6). 
The JMAM1 and JMAM3 mAbs inhibited the prolif-
eration of MSTO-211H cells as a function of their dose. 
Thus, proliferation was reduced by at least 50 and 40 % 
by 0.4 μg/ml of JMAM1 or JMAM3 mAbs, respectively. 
(See figure on previous page.)  
Fig. 4 Immunocytochemistry of clinical cases. a Papanicolaou; b Giemsa; c JMAM1; d JMAM2; e JMAM3; f JMAM4. Original magnification 400×. The 
malignant mesothelioma smear specimens, prepared from pleural effusions. Case 1 JMAM1, JMAM2, JMAM3, and JMAM4 mAbs stained membranes. 
JMAM2 mAb stained membranes and the cytoplasm. Case 2 All mAbs stained membranes. Case 3 JMAM1 and JMAM4 mAbs stained membranes; 
JMAM2 and JMAM3 mAbs stained membranes and cytoplasm
b
c




Papanicolaou Giemsa      JMAM1 JMAM2 JMAM3 JMAM4
JMAM1 JMAM2 JMAM3 JMAM4- controlH E
Fig. 5 Histopathology and cytological findings of reactive mesothelial cells, normal pleura and lung, with immunoreactive features. a Pleural effu-
sion (reactive mesothelial cells, 1000×). b Normal pleura (400×). c Normal lung (400×)
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The JMAM2 mAb inhibited cell proliferation to some 
extent. The JMAM4 mAb did not inhibit the proliferation 
of MSTO-211H cells. These results indicate that JMAM1 
and JMAM2 mAbs may be useful for treating patients 
with mesothelioma, at least those with the epithelioid 
phenotype.
Analysis of the effect of JMAM mAbs on migration 
of mesothelioma cells
Cell motility is an essential process of tumor metasta-
sis and progression. Therefore, we investigated whether 
the mAbs would affect the migration of mesothelioma 
cells using a wound-healing assay. The anti-mesotheli-
oma mAbs JMAM1, JMAM2, and JMAM3 significantly 
inhibited the ability of NCI-H226 cells to migrate to and 
close an experimentally induced wound (Fig.  7). These 
results show that the anti-mesothelioma mAbs inhib-
ited the motility of mesothelioma cells and suggest that 
the JMAM1–4 mAbs may possess a remarkable ability to 
inhibit the progression of mesotheliomas.
Analysis of the effect of JMAM mAbs on invasion 
of mesothelioma cells
We assessed the cell invasion ability of mesothelioma 
NCI-H226 cells. Significant inhibition of invasion was 
observed by JMAM mAbs compared with control mouse 
IgG1 Ab (Fig.  8). JMAM1 mAb significantly decreased 
the trans membrane migration of NCI-H226 cells com-
pared with cells treated with the mouse IgG1 isotype 
control.
Discussion
Differentiating between a mesothelioma and a papillary 
adenocarcinoma is sometimes very difficult [25]. Clini-
cians recommend that the definitive diagnosis of meso-
thelioma may be achieved using immunohistochemical 
analysis of cytological or histological specimens with cur-
rently available antibodies [8]. Many mAbs are developed 
for the diagnosis of and therapy for mesothelioma. Pre-
viously, we focused on CD26 as a novel therapeutic tar-
get for mesothelioma and have developed a humanized 
anti-CD26 mAb (clone: YS110), which is currently being 
evaluated in a phase I clinical trial for patients with malig-
nant mesothelioma [26]. We also developed anti-human 
CD26 mAbs (clone: 1F7, 5F8) that clearly and reliably 
detect the denatured CD26 molecule in formalin-fixed 
paraffin-embedded tissue [27]. Although many antibod-
ies are available to aid diagnosis, no single antibody can 
unambiguously distinguish mesotheliomas from other 
carcinomas. Anti-CD26 mAb reacts with epithelial and 
sarcomatoid mesotheliomas. However, anti-CD26 mAb 









































































Fig. 6 Proliferation of MSTO-211H cells in the presence of JMAM1–4 mAbs. JMAM1–4 mAbs were added at the indicated concentrations to cultures 
of MSTO-211H mesothelioma cells. JMAM1, P < 0.05; JMAM2, P = 0.1; JMAM3, P < 0.05; JMAM4, P = 0.18
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Anti-mesothelin mAbs react with epithelial but not sarco-
matoid mesotheliomas [13]. In contrast, JMAM1, JMAM2, 
and JMAM3 mAbs react with both subtypes. Anti-meso-
thelin mAbs react with renal cell carcinomas and pancre-
atic and ovarian cancers [28–30], unlike the JMAM4 mAbs 
that did not react with lung, ovarian, or renal cell carcino-
mas or any of the other cancer cell lines tested. JMAM1 
mAb did not cross-react with other carcinoma cell lines 
except for small-cell-type lung cancer cell lines and renal 
cell carcinoma cell lines. Taken together, our newly gen-
erated mAbs are more specific for mesothelioma than 
other diagnostic mAbs and may be helpful in the differen-
tial diagnosis of mesothelioma. Novel anti-mesothelioma 
mAbs may either serve as tools to diagnose mesotheliomas 
as stand-alone reagents or together with other diagnostic 
mAbs.
It is now commonly accepted that therapeutic mAbs 
dramatically improve the treatment of cancer patients. 
However, after repeated therapy, not all patients 
respond to therapeutic mAbs [31] because clones appear 
during the course of treatment those do not express the 
target. Therefore, additional therapeutic options are 
required to treat these patients. Common therapeutic 
mAbs against cell surface molecules exert their effects 
largely through immunological mechanisms, including 
complement-dependent cytotoxicity (CDC) and anti-
body-dependent cellular cytotoxicity (ADCC). ADCC 
and CDC may not be effective for treating patients with 
cancer because the patients may be immunocompro-
mised due to radiation, chemotherapy, and the malig-
nancy itself. However, in addition to indirectly inducing 
Fc-dependent cell death, several mAbs possess a direct 
antitumor effect that induces cell arrest or programmed 
cell death [32, 33].
Therefore, in this study, we investigated reactivity 
with mesothelioma cells as well as the direct antitumor 
effect of the newly generated anti-mesothelioma mAbs. 
We found that JMAM1 and JMAM3 mAbs inhibited the 
proliferation of the MSTO-211H mesothelial cell line, 
and JMAM1–4 mAbs inhibited wound closure by NCI-
H226 cells to varying degrees. JMAM1–4 also inhibited 
invasion of NCI-H226 cells to various degrees. Unfor-
tunately, we did not identify the target molecules of 
JMAM1–4 mAbs. Nevertheless, the promising anti-mes-
othelioma activities of these antibodies warrant contin-
ued studies in vitro and in vivo that will include efforts 
to identify their targets. Our strategy for generating 
diagnostic and therapeutic mAbs specific for tumor cells 
differs from those of conventional methods that employ 



















































Fig. 7 Wound-healing assays. a Representative images of wound closure assays after NCI-H226 cells were incubated with anti-mesothelioma anti-
bodies or control mouse IgG. b The extent of wound closure was calculated by analyzing the scratched area covered by the cells after 24 h using 
ImageJ software. The data were normalized to the control values. The data are represented as the mean ± SD of three independent experiments. 
*P < 0.05; treated versus IgG control
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immunized a mouse with three different mesothelioma 
cell lines and screened the antibodies using a different 
mesothelioma cell line to potentially obtain novel mAbs 
that react with unknown targets on the surface of meso-
thelioma cells.
Conclusion
Newly established anti-mesothelioma mAbs, JMAM1–
4, are potentially useful as diagnostic and therapeutic 
agents for mesothelioma. Moreover, our novel strat-
egy for establishing anti-tumor mAbs may facilitate the 
development of new diagnostic and therapeutic tech-
niques for other malignancies as well as mesothelioma.
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Fig. 8 Analysis of the effect of JMAM mAbs on invasion of mesothelioma cells. Cells (NCI-H226) were seeded into the upper chamber and the lower 
chamber was filled with medium as described in the “Methods” section. Photos were captured by a light microscope at ×200 (a). The migration 
of cells was measured by counting the migrating cells on the lower surface of the membrane in 3 fields (b). JMAM1, *P < 0.05; JMAM2, P = 0.12; 
JMAM3, P = 0.08; JMAM4, P = 0.18. Each mAb treated versus IgG control
Page 13 of 13Mizutani et al. BMC Res Notes  (2016) 9:324 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Received: 20 August 2015   Accepted: 16 June 2016
References
 1. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung 
Cancer. 2005;49(Suppl 1):S3–8.
 2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 
2005;5:397–408.
 3. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, 
Pass HI, Yang H. Malignant mesothelioma: facts, myths and hypotheses. J 
Cell Physiol. 2012;227:44–58.
 4. US Department of the Interior, US Geological Survey. Mineral commodity 
summaries 2015. 2015. p. 22–23.
 5. Nguyen G, Akin MM, Villanueva RR, Slatnik J. Cytopathology of malignant 
mesothelioma of the pleura in fine-needle aspiration biopsy. Diagn 
Cytopathol. 1999;21:253–9.
 6. Whitaker D. The cytology of malignant mesothelioma. Cytopathology. 
2000;11:139–51.
 7. Fassina A, Fedeli U, Corradin M, Da FM, Fabbris L. Accuracy and reproduc-
ibility of pleural effusion cytology. Leg Med. 2008;10:20–5.
 8. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and 
cytokeratin (CK903 and CK5/6) immunostains in differentiating adeno-
carcinoma, squamous cell carcinoma, and malignant mesothelioma in 
effusions. Diagn Cytopathol. 2008;36:20–5.
 9. Chung A, Inai K, Samet J. Tumor of the pleura. In: Travis WD, Muller BE, 
Hermelink HK, Harris CG, editors. Pathology and genetics. Tumours of the 
lung, pleura, thymus and heart. Lyon: IARC Press; 2004. p. 128–42.
 10. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J 
Med. 2005;353:1591–603.
 11. Inai K. Pathology of mesothelioma. Environ Health Prev Med. 
2008;13:60–4.
 12. Ordóñez NG. Immunohistochemical diagnosis of epithelioid meso-
theliomas: a critical review of old markers, new markers. Hum Pathol. 
2002;33:953–67.
 13. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of 
mesothelioma. Mod Pathol. 2003;16:192–7.
 14. Betta P, Magnani C, Bensi T, Trincheri FN, Oreccha S. Immunohistochem-
istry and molecular diagnostics of pleural malignant mesothelioma. Arch 
Pathol Lab Med. 2012;136:253–61.
 15. Takeshima Y, Inai K, Amatha V, Gemba K, Aoe K, Fujimoto N, Kato K, 
Kishimoto T. Accurancy of pathological diagnosis of mesothelioma 
cases in Japan: clinicopathological analysis of 382 cases. Lung Cancer. 
2009;66:191–7.
 16. Kao CS, Vardy J, Chatfield M, Corte P, Pavlakis N, Clarke C, Zandwijk NV, 
Clarke S. Validation of prognostic factors in malignant pleural mesothe-
lioma. Clin Lung Cancer. 2013;14:70–7.
 17. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto 
S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C. Humanized 
Anto-CD26 monoclonal antibody as a treatment for malignant mesothe-
lioma tumors. Clin Cancer Res. 2007;13:4191–200.
 18. Yamada K, Hayashi M, Du W, Ohnuma K, Sakamoto M, Morimoto C. 
Yamada T. cc. Cancer Cell International. 2009;9:17.
 19. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody 
of predefined specificity. Nature. 1975;256:495–7.
 20. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colo-
rectal carcinoma antigens detected by hybridoma antibodies. Somatic 
Cell Genet. 1979;5:957–72.
 21. Bast CR, Feeney M, Lazarus H, Nadler LM, Colvin BR, Knapp CR. Reactivity 
of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 
1981;68:1331–7.
 22. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart 
JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis 
T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy 
in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 
1997;90(6):2188–95.
 23. Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M, Hino O. Establish-
ment of novel monoclonal antibody to human ERC/mesothelin useful 
for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int. 
2009;59:161–6.
 24. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. 
Differential responses of human tumor cell lines to anti-p185HER2 mono-
clonal antibodies. Cancer Immunol Immunother. 1993;37:255–63.
 25. Kwee WS, Veldhuizen RW, Alons CA, Morawetz F, Boon ME. Quantitative 
and qualitative differences between benign and malignant mesothelial 
cells in pleural fluid. Acta Cytol. 1982;26:401–6.
 26. Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, 
Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C. CD26 
overexpression is associated with prolonged survival and enhanced 
chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res. 
2012;18:1447–56.
 27. Hatano R, Yamada T, Matsuoka S, Iwata S, Yamazaki H, Komiya E, Okamoto 
T, Dang NM, Ohnuma K, Morimoto C. Establishment of monoclonal anti-
human CD26 antibodies suitable for immunostaining of formalin-fixed 
tissue. Diagn Pathol. 2014. doi:10.1186/1746-1596-9-30.
 28. Robinson BW, Creaney J, Lake R, Nowark A, Musk AW, de Klerk N, Winzell 
P, Hellstrom KE, Helstrom I. Mesothelin-family proteins and diagnosis of 
mesothelioma. Lancet. 2003;362:1612–6.
 29. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, Yang Y, Hellstrom KH. 
Mesothelin variant 1 is released from tumor cells as a diagnostic marker. 
Cancer Epidemiol Biomark Prev. 2006;15:1014–20.
 30. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I. 
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor 
family are detectable in sera from patients with ovarian carcinoma. Proc 
Natl Acad Sci USA. 1999;6:11531–6.
 31. O’Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lemer 
S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic 
leukemia. J Clin Oncol. 2001;19:2165–70.
 32. Matsuoka S, Asano Y, Sano K, Kishimto H, Yamashita I, Yorifuji H, Utsuyama 
M, Hirokawa K, Tada T. A novel type of cell death of lymphocytes induced 
by a monoclonal antibody without participation of lymphocytes. J Exp 
Med. 1995;181:2007–15.
 33. Yuniel FM, Alejandro LR. Lonely killers. mAbs. 2008;3:528–34.
